Master clinical nephrology
Real-world cases written the way you manage patients, from the first call to follow-up. Built for daily practice, consultant and fellowship exams, and any nephrology interview.
- 183+ topics
- 11 areas
- 3 free to read
Nephrology topics
Clinical topics written the way you manage patients. Pick an area, or search for a problem.
22 topics in CKD & Bone-Mineral Clear
Studying for the viva? Exam cases Archive 118- Cinacalcet versus etelcalcetide: how do you choose, prescribe and switch in dialysis secondary hyperparathyroidism? Oral daily versus IV after HD: both activate the calcium-sensing receptor and lower PTH; etelcalcetide gives supervised dosing and stronger...
- Kidney transplant recipient 18 months out with calcium 12.2 mg/dL, PTH 850 and nephrocalcinosis: cinacalcet or parathyroidectomy? Bottom line: this is persistent (tertiary) hyperparathyroidism after transplant, with symptomatic hypercalcaemia beyond 12 months and nephro...
- Dialysis patient two days after parathyroidectomy, tingling and calcium 6.5 mg/dL: hungry bone syndrome, how do you recognise it, treat it and prevent it? Bottom line: after parathyroidectomy for severe secondary hyperparathyroidism, a sudden PTH fall lets bone take up calcium unopposed: profou...
- Weight Loss in CKD Stage 5 Before Dialysis: Work-up and Management Weight loss in a CKD 5 patient who is not on dialysis is protein-energy wasting (PEW) until proven otherwise, but unexplained loss unrelated...
- A patient on an SGLT2 inhibitor presents unwell with vomiting and abdominal pain and a high anion-gap acidosis but a glucose under 14 mmol/L: recognise and manage euglycaemic DKA Bottom line: an unwell patient on an SGLT2 inhibitor with a high anion gap acidosis has euglycaemic ketoacidosis until proven otherwise, eve...
- Osteoporosis and fracture risk in CKD G4-5D: how do you choose between denosumab, teriparatide and bisphosphonates? Bottom line: in G4-5D I first correct the CKD-MBD biochemistry (PTH, phosphate, vitamin D), consider a bone biopsy, then choose: denosumab w...
- Weight loss in a CKD 5 / pre-dialysis patient: uraemia and protein-energy wasting vs malignancy, infection, depression, GI and endocrine causes; work-up and when it is an indication to start dialysis Bottom line: weight loss in CKD 5 is protein-energy wasting until proven otherwise, but unexplained loss unrelated to intake or dialysis ade...
- Drug Dosing in CKD and Dialysis Drug dosing in CKD is a four-part answer. (1) Which GFR - eGFR from creatinine for most drugs, cystatin-based or measured GFR for narrow-win...
- Conservative Kidney Management and Dialysis Withdrawal Comprehensive conservative kidney management (CKM) is planned, holistic, patient-centred care for CKD G5 that does not include dialysis: sha...
- CKD: KDIGO 2024 Definition, CGA Classification, Screening, Work-up and Referral Chronic kidney disease (CKD) is, per KDIGO 2024, abnormalities of kidney structure or function, present for a minimum of 3 months, with impl...
- Diabetic Kidney Disease — SGLT2i / Finerenone / GLP-1 Diabetic kidney disease (DKD) is diagnosed clinically in typical cases (long-standing diabetes, retinopathy, gradual proteinuria) — biopsy i...
- Metabolic Acidosis in CKD — Bicarbonate & Diet Metabolic acidosis in CKD is a normal-anion-gap (non-AG) acidosis from impaired renal ammoniagenesis and acid excretion as nephron mass fall...
- CKD-MBD / Secondary Hyperparathyroidism / Phosphate Binders CKD-MBD (mineral and bone disorder) is a near-universal exam case: phosphate retention, low calcitriol, and high FGF23 drive secondary hyper...
- Anemia of CKD — ESA / HIF-PHI / Iron Anemia of CKD is driven mainly by relative erythropoietin deficiency from peritubular interstitial fibroblasts, compounded by iron deficienc...
- CKD Progression — 4-Pillar Evidence-Based Therapy The examiner wants ALL evidence-based pillars to slow CKD progression, by name, with trial evidence: ACEi/ARB, SGLT2 inhibitor, finerenone (...
- CKD-MBD in non-dialysis CKD G3a-G5: phosphate, PTH, vitamin D and bone tests Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism due to CKD. It manifests as...
- Ramadan Fasting in CKD: Complete Risk Stratification & Scenarios Managing Chronic Kidney Disease (CKD) patients during Ramadan requires a meticulous, individualized approach. The decision to fast is not bi...
- Aluminium Toxicity in Dialysis: Deferoxamine Challenge and Bone Disease Aluminum toxicity, once a common scourge of dialysis patients due to contaminated water and aluminum-based phosphate binders, is now rare bu...
- Hyperparathyroidism with hyperphosphatemia on dialysis: why not paricalcitol first? Managing secondary hyperparathyroidism (SHPT) in the setting of hyperphosphatemia requires a strategic, stepwise approach. Hyperphosphatemia...
- Calciphylaxis (calcific uremic arteriolopathy): management bundle Calciphylaxis, or Calcific Uremic Arteriolopathy (CUA), is a life-threatening vasculopathy characterized by calcification of cutaneous arter...
- CKD outpatient work-up: eGFR, urine ACR, sediment and ultrasound in a 60-year-old with eGFR 55 From your uploaded resources: The initial outpatient workup for a patient with suspected or newly diagnosed Chronic Kidney Disease (CKD) is...
- Slowing CKD Progression: BP Target, RAS Blockade, SGLT2 Inhibitors and Diet Numbers Slowing the progression of Chronic Kidney Disease (CKD) is a cornerstone of modern nephrology. The goal is to preserve remaining kidney func...